Strategic Partners A/S

Strategic Partners A/S Assets per Share

The Total Assets per Share of Strategic Partners A/S (STRAP.CO) as of Oct 16, 2026 is 488.48 DKK. In the previous year, Total Assets per Share was 588.95 DKK — a change of -17.06% (lower).

Assets per Share

488.48DKK

YoY

-17.06%

Last updated:

Total Assets per Share of Strategic Partners A/S is 2025 488.48 DKK. Total Assets per Share of Strategic Partners A/S was 2024 588.95 DKK. It decreases by -17.06% lower compared to the previous year.

The Strategic Partners A/S Assets per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Assets per Share
Date
Assets per Share
Jan 1, 2018
11,033.73 DKK
Jan 1, 2019
4,518.85 DKK
Jan 1, 2020
20,562.33 DKK
Jan 1, 2021
4,330.73 DKK
Jan 1, 2022
1,420.65 DKK
Jan 1, 2023
482.80 DKK
Jan 1, 2024
588.95 DKK
Jan 1, 2025
488.48 DKK
The Strategic Partners A/S Assets per Share history
YEARAssets per ShareYoY
488.48DKK-17.06%
588.95DKK+21.99%
482.80DKK-66.02%
1,420.65DKK-67.20%
4,330.73DKK-78.94%
20,562.33DKK+355.03%
4,518.85DKK-59.05%
11,033.73DKK-33.41%
16,570.43DKK+1,975.13%
798.53DKK-62.40%
2,123.80DKK-10.90%
2,383.67DKK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Strategic Partners A/S Stock analysis

What does Strategic Partners A/S do? Strategic Partners A/S, listed on the Copenhagen Stock Exchange with ticker STRAP.CO and ISIN DK0062502894, is a Danish biotechnology company operating in the healthcare sector. Based in Copenhagen, the company employs 141 people and went public through an IPO on November 17, 2017. Strategic Partners A/S focuses on the development of treatments for rare diseases, particularly targeting lysosomal storage diseases (LSDs) and protein aggregation disorders. LSDs encompass approximately 50 genetic disorders caused by deficiencies in lysosomal enzymes or other lysosomal components. The company's primary therapeutic candidate, arimoclomol, works by stimulating the production of heat shock proteins, which assist in correcting misfolded proteins or facilitating their removal via lysosomal recycling. Strategic Partners A/S collaborates with academic institutions across Europe and the United States to advance its research and development efforts. The company's website is hosted at https://www.orphazyme.com/, though the provided source description includes unverified details about Orphazyme A/S, which should not be conflated with Strategic Partners A/S. Strategic Partners A/S is dedicated to addressing life-threatening and debilitating rare diseases through innovative biotechnological approaches. The company's operations are centered on preclinical development, with a focus on advancing therapies that target the underlying mechanisms of genetic disorders. Strategic Partners A/S maintains a strong presence in the biotechnology sector, leveraging partnerships and scientific expertise to develop treatments for conditions with limited therapeutic options. The company's activities are aligned with the broader healthcare industry's focus on rare disease research and treatment innovation. Strategic Partners A/S continues to work toward bringing novel therapies to patients suffering from rare and complex genetic disorders. Strategic Partners A/S is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Strategic Partners A/S stock

Total Assets per Share of Strategic Partners A/S is 488.48 DKK in 2025.

Total Assets per Share of Strategic Partners A/S changed from 588.95 DKK to 488.48 DKK, representing a -17.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Total Assets per Share Strategic Partners A/S since 2006 – with annual values, charts, and detailed analysis.

Assets per share divides total assets by shares outstanding, indicating the total resource base backing each share of stock.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Other — Strategic Partners A/S

All Key Metrics — Strategic Partners A/S